Search details
1.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Article
in English
| MEDLINE | ID: mdl-37524096
2.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Article
in English
| MEDLINE | ID: mdl-33592176
3.
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Cancer
; 127(17): 3194-3201, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-33882143
4.
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Prostate
; 78(2): 121-127, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29105802
5.
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
JAMA
; 319(18): 1880-1888, 2018 05 08.
Article
in English
| MEDLINE | ID: mdl-29801011
6.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Clin Cancer Res
; 30(1): 33-38, 2024 01 05.
Article
in English
| MEDLINE | ID: mdl-37882676
7.
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Clin Cancer Res
; 30(2): 444-449, 2024 01 17.
Article
in English
| MEDLINE | ID: mdl-37966367
8.
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
Eur Urol
; 2024 May 28.
Article
in English
| MEDLINE | ID: mdl-38811313
9.
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
JAMA Netw Open
; 6(8): e2326546, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37526936
10.
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Eur Urol
; 84(6): 536-544, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37596191
11.
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Eur Urol
; 84(3): 341-347, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37414705
12.
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Eur Urol Oncol
; 6(5): 516-524, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37087309
13.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
J Clin Oncol
; 40(28): 3301-3309, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35446628
14.
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Clin Cancer Res
; 28(2): 271-278, 2022 01 15.
Article
in English
| MEDLINE | ID: mdl-34716198
15.
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
Clin Cancer Res
; 27(9): 2435-2441, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33568346
16.
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Clin Cancer Res
; 27(7): 1967-1973, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33500355
17.
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
J Immunother Cancer
; 9(8)2021 08.
Article
in English
| MEDLINE | ID: mdl-34380663
18.
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.
Bladder Cancer
; 6(2): 123-129, 2020 Jun 11.
Article
in English
| MEDLINE | ID: mdl-32793789
19.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Clin Cancer Res
; 26(10): 2290-2296, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-31969335
20.
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).
Kidney Cancer
; 3(2): 111-118, 2019 Aug 07.
Article
in English
| MEDLINE | ID: mdl-31763512